Table 2 Overview of NK cell-based immunotherapies in clinical trials for pediatric AML (R/R: relapse/refractory).
From: Targeting the innate immune system in pediatric and adult AML
Therapy | Disease stage | Age (in years) | Phase | Conditioning therapy | Year | NCT |
|---|---|---|---|---|---|---|
NK cell transplant (haploidentical) | R/R AML | <30 | 2 | Chemotherapy (Busulfan, cyclophosphamide) | 2007–2020 | NCT00553202 |
R/R AML | <120 | 2 | Chemotherapy (Cyclophosphamide, fludarabine) | 2007–2016 | NCT00526292 | |
BM transplantation within the past 4–6 weeks | <65 | 1 | – | 2007–2013 | NCT00569283 | |
R/R AML | >2 | 2 | Chemotherapy (Cyclophosphamide, fludarabine) | 2006–2017 | NCT00274846 [159] | |
R/R AML | <18 | 2 | Chemotherapy (Cyclophosphamide, fludarabine) | 2009–2010 | NCT00871689 | |
R/R AML | 4–35 | 1 | Stem cell infusion | 2011–2019 | NCT01287104 [160] | |
Umbilical cord blood transplant | R/R AML | <18 | 2 | Chemotherapy (Cyclophosphamide, fludarabine), Total-body irradiation | 2009–2012 | NCT00871689 |
R/R AML | <45 | 2 | Chemotherapy, Radiation | 2006–2012 | NCT00354172 | |
Memory-like NK | R/R AML | 1–21 | 2 | Chemotherapy (Fludarabine, Ara-C) | 2020–ongoing | NCT04354025 |
R/R AML | >1 | 2 | CD3+ T Cell Product Infusion | 2017–ongoing | NCT03068819 [151] | |
R/R AML | >2 | 2 | Chemotherapy (Cyclophosphamide, fludarabine), IL-2 | 2013–2023 | NCT01898793 [161] | |
Anti-CD38 and FT538 (target therapy) | R/R AML | >11 | 1 | Chemotherapy (Cyclophosphamide, fludarabine) | 2021–ongoing | NCT04714372 |
TriKe (CD163-NKp46-CD16a) | R/R AML | >1 | 1 2 | – | 2021–ongoing | NCT05086315 |
JK500 cell injection | R/R AML | <18 | Early 1 | 2022–ongoing | NCT05519384 |
